GSK3389404

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Hepatitis B

Phase 1

First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects

CompletedNCT02647281

GlaxoSmithKlineHepatitis B

Start: 2015-12-17End: 2017-01-03Updated: 2019-07-16

Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects

CompletedNCT03020745

GlaxoSmithKlineHepatitis B

Start: 2017-02-14End: 2019-11-06Updated: 2020-10-01

Related Papers

Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies.

2024-05-252 citations

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.

2022-12-124 citations

Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.

2022-06-1537 citations